Table 3. Open in new tab Independent...

	Progression-Free Survival				Overall Survival
A
CDKN2A	.8471	.9387	0.95	0.57–1.58	.0089	.0178	0.49	0.28–0.83
CDKN2B	.9387	.9387	0.98	0.58–1.65	.0041	.0110	0.45	0.26–0.78
EGFR	.4060	.9387	0.76	0.40–1.45	.0044	.0110	0.35	0.17–0.72
NF1	.8088	.9387	1.18	0.31–4.57	.7254	.8060	0.76	0.16–3.52
PDGFRA	.0441	.2675	12.98	1.07–157.37	.2833	.3541	3.15	0.39–25.59
PIK3CA	.5117	.9387	0.63	0.16–2.52	.2000	.2857	0.37	0.08–1.69
PTEN	.7663	.9387	1.11	0.57–2.14	.0303	.0505	0.43	0.20–0.92
TERT promoter	.5856	.9387	0.88	0.56–1.38	.0002	.0020	0.40	0.25–0.65
TP53	.2544	.848	0.63	0.28–1.4	.0034	.0110	0.26	0.10–0.64
IDH1/2	.0535	.2675	28.76	0.95–869.79	.9998	.9998	0.0	0-.
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation
B
CDKN2A	.8471	.9387	0.95	0.57–1.58	.0224	.0403	0.53	0.31–0.91
CDKN2B	.9387	.9387	0.98	0.58–1.65	.0089	.0267	0.48	0.28–0.83
EGFR	.4060	.9387	0.76	0.4–1.45	.0044	.0198	0.35	0.17–0.72
NF1	.8088	.9387	1.18	0.31–4.57	.7254	.7254	0.76	0.16–3.52
PDGFRA	.0441	.3969	12.98	1.07–157.37	.3039	.3907	2.99	0.37–24.03
PIK3CA	.5117	.9387	0.63	0.16–2.52	.4283	.4818	0.56	0.13–2.37
PTEN	.7663	.9387	1.11	0.57–2.14	.0303	.0455	0.43	0.20–0.92
TERT promoter	.5856	.9387	0.88	0.56–1.38	.0005	.0045	0.42	0.26–0.69
TP53	.2544	.9387	0.63	0.28–1.40	.0135	.0304	0.29	0.11–0.78
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, IDH1/2 mutation

Progression-Free Survival

Overall Survival

Gene mutation

FDR-adjusted P value

95% CI

P value

FDR-adjusted P value

95% CI

CDKN2A

.8471

.9387

0.95

0.57–1.58

.0089

.0178

0.49

0.28–0.83

CDKN2B

.9387

0.98

0.58–1.65

.0041

.0110

0.45

0.26–0.78

EGFR

.4060

.9387

0.76

0.40–1.45

.0044

.0110

0.35

0.17–0.72

NF1

.8088

.9387

1.18

0.31–4.57

.7254

.8060

0.76

0.16–3.52

PDGFRA

.0441

.2675

12.98

1.07–157.37

.2833

.3541

3.15

0.39–25.59

PIK3CA

.5117

.9387

0.63

0.16–2.52

.2000

.2857

0.37

0.08–1.69

PTEN

.7663

.9387

1.11

0.57–2.14

.0303

.0505

0.43

0.20–0.92

TERT promoter

.5856

.9387

0.88

0.56–1.38

.0002

.0020

0.40

0.25–0.65

TP53

.2544

.848

0.63

0.28–1.4

.0034

.0110

0.26

0.10–0.64

IDH1/2

.0535

.2675

28.76

0.95–869.79

.9998

0.0

0-.

Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation

CDKN2A

.8471

.9387

0.95

0.57–1.58

.0224

.0403

0.53

0.31–0.91

CDKN2B

.9387

0.98

0.58–1.65

.0089

.0267

0.48

0.28–0.83

EGFR

.4060

.9387

0.76

0.4–1.45

.0044

.0198

0.35

0.17–0.72

NF1

.8088

.9387

1.18

0.31–4.57

.7254

0.76

0.16–3.52

PDGFRA

.0441

.3969

12.98

1.07–157.37

.3039

.3907

2.99

0.37–24.03

PIK3CA

.5117

.9387

0.63

0.16–2.52

.4283

.4818

0.56

0.13–2.37

PTEN

.7663

.9387

1.11

0.57–2.14

.0303

.0455

0.43

0.20–0.92

TERT promoter

.5856

.9387

0.88

0.56–1.38

.0005

.0045

0.42

0.26–0.69

TP53

.2544

.9387

0.63

0.28–1.40

.0135

.0304

0.29

0.11–0.78

Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, IDH1/2 mutation

	Progression-Free Survival				Overall Survival
A
CDKN2A	.8471	.9387	0.95	0.57–1.58	.0089	.0178	0.49	0.28–0.83
CDKN2B	.9387	.9387	0.98	0.58–1.65	.0041	.0110	0.45	0.26–0.78
EGFR	.4060	.9387	0.76	0.40–1.45	.0044	.0110	0.35	0.17–0.72
NF1	.8088	.9387	1.18	0.31–4.57	.7254	.8060	0.76	0.16–3.52
PDGFRA	.0441	.2675	12.98	1.07–157.37	.2833	.3541	3.15	0.39–25.59
PIK3CA	.5117	.9387	0.63	0.16–2.52	.2000	.2857	0.37	0.08–1.69
PTEN	.7663	.9387	1.11	0.57–2.14	.0303	.0505	0.43	0.20–0.92
TERT promoter	.5856	.9387	0.88	0.56–1.38	.0002	.0020	0.40	0.25–0.65
TP53	.2544	.848	0.63	0.28–1.4	.0034	.0110	0.26	0.10–0.64
IDH1/2	.0535	.2675	28.76	0.95–869.79	.9998	.9998	0.0	0-.
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation
B
CDKN2A	.8471	.9387	0.95	0.57–1.58	.0224	.0403	0.53	0.31–0.91
CDKN2B	.9387	.9387	0.98	0.58–1.65	.0089	.0267	0.48	0.28–0.83
EGFR	.4060	.9387	0.76	0.4–1.45	.0044	.0198	0.35	0.17–0.72
NF1	.8088	.9387	1.18	0.31–4.57	.7254	.7254	0.76	0.16–3.52
PDGFRA	.0441	.3969	12.98	1.07–157.37	.3039	.3907	2.99	0.37–24.03
PIK3CA	.5117	.9387	0.63	0.16–2.52	.4283	.4818	0.56	0.13–2.37
PTEN	.7663	.9387	1.11	0.57–2.14	.0303	.0455	0.43	0.20–0.92
TERT promoter	.5856	.9387	0.88	0.56–1.38	.0005	.0045	0.42	0.26–0.69
TP53	.2544	.9387	0.63	0.28–1.40	.0135	.0304	0.29	0.11–0.78
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, IDH1/2 mutation

Table 3.

Open in new tab

Independent Prognostic Value of Gross Total Resection Versus Other Extent of Resection Among Patients With Specific Gene Mutations, Using Multivariate Analysis and Multiple Comparisons

	Progression-Free Survival				Overall Survival
Gene mutation	P	FDR-adjusted P value	HR	95% CI	P value	FDR-adjusted P value	HR	95% CI
A
CDKN2A	.8471	.9387	0.95	0.57–1.58	.0089	.0178	0.49	0.28–0.83
CDKN2B	.9387	.9387	0.98	0.58–1.65	.0041	.0110	0.45	0.26–0.78
EGFR	.4060	.9387	0.76	0.40–1.45	.0044	.0110	0.35	0.17–0.72
NF1	.8088	.9387	1.18	0.31–4.57	.7254	.8060	0.76	0.16–3.52
PDGFRA	.0441	.2675	12.98	1.07–157.37	.2833	.3541	3.15	0.39–25.59
PIK3CA	.5117	.9387	0.63	0.16–2.52	.2000	.2857	0.37	0.08–1.69
PTEN	.7663	.9387	1.11	0.57–2.14	.0303	.0505	0.43	0.20–0.92
TERT promoter	.5856	.9387	0.88	0.56–1.38	.0002	.0020	0.40	0.25–0.65
TP53	.2544	.848	0.63	0.28–1.4	.0034	.0110	0.26	0.10–0.64
IDH1/2	.0535	.2675	28.76	0.95–869.79	.9998	.9998	0.0	0-.
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation
B
CDKN2A	.8471	.9387	0.95	0.57–1.58	.0224	.0403	0.53	0.31–0.91
CDKN2B	.9387	.9387	0.98	0.58–1.65	.0089	.0267	0.48	0.28–0.83
EGFR	.4060	.9387	0.76	0.4–1.45	.0044	.0198	0.35	0.17–0.72
NF1	.8088	.9387	1.18	0.31–4.57	.7254	.7254	0.76	0.16–3.52
PDGFRA	.0441	.3969	12.98	1.07–157.37	.3039	.3907	2.99	0.37–24.03
PIK3CA	.5117	.9387	0.63	0.16–2.52	.4283	.4818	0.56	0.13–2.37
PTEN	.7663	.9387	1.11	0.57–2.14	.0303	.0455	0.43	0.20–0.92
TERT promoter	.5856	.9387	0.88	0.56–1.38	.0005	.0045	0.42	0.26–0.69
TP53	.2544	.9387	0.63	0.28–1.40	.0135	.0304	0.29	0.11–0.78
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, IDH1/2 mutation

	Progression-Free Survival				Overall Survival
Gene mutation	P	FDR-adjusted P value	HR	95% CI	P value	FDR-adjusted P value	HR	95% CI
A
CDKN2A	.8471	.9387	0.95	0.57–1.58	.0089	.0178	0.49	0.28–0.83
CDKN2B	.9387	.9387	0.98	0.58–1.65	.0041	.0110	0.45	0.26–0.78
EGFR	.4060	.9387	0.76	0.40–1.45	.0044	.0110	0.35	0.17–0.72
NF1	.8088	.9387	1.18	0.31–4.57	.7254	.8060	0.76	0.16–3.52
PDGFRA	.0441	.2675	12.98	1.07–157.37	.2833	.3541	3.15	0.39–25.59
PIK3CA	.5117	.9387	0.63	0.16–2.52	.2000	.2857	0.37	0.08–1.69
PTEN	.7663	.9387	1.11	0.57–2.14	.0303	.0505	0.43	0.20–0.92
TERT promoter	.5856	.9387	0.88	0.56–1.38	.0002	.0020	0.40	0.25–0.65
TP53	.2544	.848	0.63	0.28–1.4	.0034	.0110	0.26	0.10–0.64
IDH1/2	.0535	.2675	28.76	0.95–869.79	.9998	.9998	0.0	0-.
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation
B
CDKN2A	.8471	.9387	0.95	0.57–1.58	.0224	.0403	0.53	0.31–0.91
CDKN2B	.9387	.9387	0.98	0.58–1.65	.0089	.0267	0.48	0.28–0.83
EGFR	.4060	.9387	0.76	0.4–1.45	.0044	.0198	0.35	0.17–0.72
NF1	.8088	.9387	1.18	0.31–4.57	.7254	.7254	0.76	0.16–3.52
PDGFRA	.0441	.3969	12.98	1.07–157.37	.3039	.3907	2.99	0.37–24.03
PIK3CA	.5117	.9387	0.63	0.16–2.52	.4283	.4818	0.56	0.13–2.37
PTEN	.7663	.9387	1.11	0.57–2.14	.0303	.0455	0.43	0.20–0.92
TERT promoter	.5856	.9387	0.88	0.56–1.38	.0005	.0045	0.42	0.26–0.69
TP53	.2544	.9387	0.63	0.28–1.40	.0135	.0304	0.29	0.11–0.78
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, IDH1/2 mutation

Bolded values indicate P < .05.

This Feature Is Available To Subscribers Only